欢迎来到OAJRC平台!

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Medical Research Frontier. 2021; 5: (1) ; 1-3 ; DOI: 10.12208/j.imrf.20210001.

Evaluation of the efficacy of TACE combined sorafenib on advanced hepatocellular carcinoma
TACE联合索拉非尼治疗中晚期肝细胞肝癌有效性探讨

作者: 胡磊*,

云南省第一人民医院昆明理工大学附属医院 云南昆明

*通讯作者: 胡磊,单位:云南省第一人民医院昆明理工大学附属医院 云南昆明;

发布时间: 2021-04-28 总浏览量: 195

摘要

目的 肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝癌的有效性探讨。方法 回顾性分析67例肝癌病患,其中对照组33例仅行TACE治疗,实验组34例加用索拉非尼,对比两组患者的用药有效率及不良反应。结果 在临床疗效方面实验组优于对照组(P<0.05);两组不良反应包括手足综合征、腹泻、皮疹、高血压和肝功能异常等,差别无统计分析意义(P>0.05)。结论 索拉非尼联合TACE治疗中晚期肝癌有效、安全,临床应用价值值得肯定。

关键词: 肝细胞癌;栓塞;索拉非尼

Abstract

Objective: Evaluation of the efficacy of TACE combined sorafenib on advanced hepatocellular carcinoma.
Methods: Retrospective analysis 67 patients with liver cancer, the control group (33 cases) only received TACE treatment, in the experimental group, 34 patients were given TACE and sorafenib, the effective rate and adverse reactions of the two groups were compared.
Results: The experimental group is superior to the Control Group in Clinical Curative Effect (P<0.05). The two groups of adverse reactions included Hand-foot syndrome, diarrhea, skin rash, hypertension and liver dysfunction, the difference was not statistically significant (P>0.05).
Conclusion  : sorafenib combined with TACE in the treatment of advanced liver cancer are effective and safe.And clinical value is worthy of affirmation.

Key words: Hepatocellular Carcinoma, Embolization, So-Rafenib

参考文献 References

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

引用本文

胡磊, TACE联合索拉非尼治疗中晚期肝细胞肝癌有效性探讨[J]. 国际医药研究前沿, 2021; 5: (1) : 1-3.